文献速递咽喉与嗓音头颈外科

45岁及以上复发性呼吸道乳头状瘤病患者加德西疫苗接种的更新研究

Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older.
PubMed 文献 · Laryngoscope · 2025-03-18

本研究对2008至2022年诊断为复发性呼吸道乳头状瘤病(RRP)的45岁以上成人进行回顾性病历审查,比较接种与未接种加德西疫苗者的手术间隔(ISI)。接种组ISI从126天显著增至304天(p=0.0039),但较此前研究的494天有所下降,提示佐剂效应可能随时间减弱。

要点

  • 接种组ISI从126天增至304天(p=0.0039),随访100.1±47.3个月。
  • 此前研究随访49.7±30.3个月时接种组ISI为494天,现降至304天。
  • 未接种组中非加德西佐剂使用对ISI无显著影响(p=0.34)。

核心结论

  • 45岁以上RRP患者使用加德西佐剂可显著延长ISI,支持此前研究结果。
  • 该效应幅度可能随时间减弱,ISI虽仍显著但从494天降至304天。
  • 数据提出是否需研究加德西加强剂量的疑问。

研究设计与样本

  • 回顾性病历审查,纳入2008至2022年诊断为RRP的45岁以上成人。
  • 接种组定义为至少接受两剂加德西疫苗。
  • 共51例患者,接种组14例,未接种组37例。

主要发现

  • 接种组ISI从126天显著增至304天(p=0.0039),随访100.1±47.3个月。
  • 此前研究随访49.7±30.3个月时接种组ISI为494天。
  • 接种组非加德西佐剂使用更多,但未接种组中非加德西佐剂使用对ISI无显著影响(p=0.34)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gardasil vaccination has been effective as primary prevention and adjuvant therapy for recurrent respiratory papillomatosis (RRP). We present an update to our previous research reporting a significant increase in the intersurgical interval (ISI) after adjuvant Gardasil vaccination. Our objectives were: (1) to assess the durability of Gardasil as an adjuvant in RRP with longer-term follow-up and an expanded cohort, and (2) to better control for the use of other non-Gardasil adjuvant therapies. METHODS: A retrospective chart review of adult patients > 45 years diagnosed with RRP from 2008 to 2022 was conducted. Patients were considered vaccinated if they received at least two Gardasil doses. RESULTS: There were 51 total patients, 14 vaccinated and 37 unvaccinated. There was a significant increase in the ISI for the vaccinated group from 126 to 304 days (p = 0.0039), with 100.1 ± 47.3 months follow-up. Our previous study, performed at 49.7 ± 30.3 months follow-up, found an ISI of 494 days in the vaccinated group. Non-Gardasil adjuvant use was greater in the vaccinated group, but we found no significant effect of non-Gardasil adjuvant use on ISI in the unvaccinated group (p = 0.34). CONCLUSIONS: Adjuvant Gardasil use in RRP patients > 45 years significantly increases the ISI, which supports findings from our previous study. However, the magnitude of this effect may wane with time, with the ISI remaining significant but downtrending from 494 to 304 days. This data raise the question of whether booster Gardasil dosing warrants investigation.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Meeker MO, Ivancic R, deSilva B, et al. Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older. Laryngoscope. 2025. PMID: 40099397. doi:10.1002/lary.32123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。